HeXun Biosciences Co (ROCO:6986) Beginning Cash Position: NT$118.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6986 HeXun Biosciences Co Ltd ROCO:6986
19 GF Score
Price NT$43.00
! 2 Warning Signs
View Full Analysis

What is HeXun Biosciences Co Beginning Cash Position?

HeXun Biosciences Co ROCO:6986 -0.23% 19 Beginning Cash Position is NT$118.2 Mil as of Jun. 2026. GuruFocus rates ROCO:6986 with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

HeXun Biosciences Co's Beginning Cash Position for the quarter that ended in Jun. 2026 was NT$118.2 Mil.

HeXun Biosciences Co's quarterly Beginning Cash Position declined from Dec. 2025 (NT$264.9 Mil) to Mar. 2026 (NT$208.2 Mil) and declined from Mar. 2026 (NT$208.2 Mil) to Jun. 2026 (NT$118.2 Mil).

HeXun Biosciences Co's annual Beginning Cash Position increased from Dec. 2023 (NT$119.7 Mil) to Dec. 2024 (NT$257.7 Mil) but then declined from Dec. 2024 (NT$257.7 Mil) to Dec. 2025 (NT$201.0 Mil).

HeXun Biosciences Co Beginning Cash Position Related Terms

HeXun Biosciences Co Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for HeXun Biosciences Co's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HeXun Biosciences Co Beginning Cash Position Chart

HeXun Biosciences Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 71.69 85.03 119.74 257.67 200.99

HeXun Biosciences Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 247.47 198.95 264.90 208.20 118.25
ROCO:6986
19GF Score
HeXun Biosciences Co Ltd ROCO:6986
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HeXun Biosciences Co Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of NT$118.2 Mil mean?
HeXun Biosciences Co (ROCO:6986) has a Beginning Cash Position of NT$118.2 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on HeXun Biosciences Co and its competitors.
Is HeXun Biosciences Co's Beginning Cash Position too high?
HeXun Biosciences Co's current Beginning Cash Position is NT$118.2 Mil. Overall, HeXun Biosciences Co has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does HeXun Biosciences Co's Beginning Cash Position compare to VRTX and REGN?
HeXun Biosciences Co's Beginning Cash Position of NT$118.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on HeXun Biosciences Co and its competitors. HeXun Biosciences Co's current Beginning Cash Position is NT$118.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HeXun Biosciences Co stock overvalued right now?
HeXun Biosciences Co (ROCO:6986) has a current Beginning Cash Position of NT$118.2 Mil. The current Beginning Cash Position is NT$118.2 Mil. HeXun Biosciences Co's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For HeXun Biosciences Co (ROCO:6986), the current Beginning Cash Position is NT$118.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HeXun Biosciences Co Business Description

Address Chunri Road, 6 F., No. 1490, Taoyuan District, Taoyuan, TWN
HeXun Biosciences Co Ltd is engaged in the research and development of cell drugs and cell derivatives. It conducts research and development jointly with medical research institutions to use stem cells to treat cardiovascular, immune-inflammatory, and neurodegenerative diseases to develop innovative cell drugs and treatment methods. The company's main business items are new drug research and development, biotechnology services, and research and development services, such as: commissioned research and development and production services for cell medicine, agency testing and development services, and biomedical consulting services, etc.
19GF Score

Get the complete analysis for ROCO:6986

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$43.00
Price